Hemostemix (2VF0) Stock Overview
A clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
2VF0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hemostemix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.043 |
| 52 Week High | CA$0.36 |
| 52 Week Low | CA$0.03 |
| Beta | 0.56 |
| 1 Month Change | 29.85% |
| 3 Month Change | 10.13% |
| 1 Year Change | -63.14% |
| 3 Year Change | -74.86% |
| 5 Year Change | n/a |
| Change since IPO | -85.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VF0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.8% | -5.1% | -3.0% |
| 1Y | -63.1% | -11.4% | 10.0% |
Return vs Industry: 2VF0 underperformed the German Biotechs industry which returned -12.4% over the past year.
Return vs Market: 2VF0 underperformed the German Market which returned 11.4% over the past year.
Price Volatility
| 2VF0 volatility | |
|---|---|
| 2VF0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2VF0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2VF0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Thomas Smeenk | hemostemix.com |
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Hemostemix Inc. Fundamentals Summary
| 2VF0 fundamental statistics | |
|---|---|
| Market cap | €10.84m |
| Earnings (TTM) | -€2.10m |
| Revenue (TTM) | n/a |
Is 2VF0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VF0 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.40m |
| Earnings | -CA$3.40m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -99.5% |
How did 2VF0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/21 07:51 |
| End of Day Share Price | 2026/01/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hemostemix Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Siddharth Rajeev | Fundamental Research Corp. |